PRME Earnings Date: Nov 6, 2026 (Estimated) — Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PRME's next earnings date?
Prime Medicine, Inc. (PRME) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $1.3M.
How did PRME do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Prime Medicine, Inc. posted EPS of -$0.24 versus the -$0.26 estimate, a beat of 4.0%. Revenue was $1.2M against a $2.3M estimate. The stock's 1-day post-earnings move was -4.2%.
How much does PRME stock move after earnings?
PRME beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.9% (up or down) in the day after earnings.
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.26 | -0.24 | +4.00% | $1.2M | ✅ Beat | -4.22% | +3.90% | +20.45% |
| 2026-05-07 | Q1 2026 | -0.25 | -0.28 | -12.00% | $856,000 | ❌ Miss | -8.65% | -4.11% | -10.26% |
| 2026-03-03 | Q4 2025 | -0.25 | -0.24 | +4.00% | $838,000 | ✅ Beat | -9.23% | -11.80% | -25.32% |
| 2025-11-07 | Q3 2025 | -0.23 | -0.32 | -39.13% | $1.2M | ❌ Miss | -8.85% | -20.33% | +0.72% |
| 2025-08-07 | Q2 2025 | -0.35 | -0.41 | -17.14% | $1.1M | ❌ Miss | -9.58% | -6.39% | -8.60% |
| 2025-02-28 | Q4 2024 | -0.37 | -0.31 | +16.22% | $2.2M | ✅ Beat | +4.13% | -4.96% | -17.77% |
| 2024-11-12 | Q3 2024 | -0.39 | -0.44 | -12.82% | $209,000 | ❌ Miss | -8.33% | -26.62% | -30.32% |
| 2024-05-10 | Q1 2024 | -0.47 | -0.44 | +6.38% | $591,000 | ✅ Beat | -1.92% | +23.08% | +34.27% |
Showing last 8 quarters.